Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy

Front Immunol. 2024 Dec 6:15:1488345. doi: 10.3389/fimmu.2024.1488345. eCollection 2024.

Xiaoyan Qi^{1

2}, Cheng Cheng^{1

3}, Dawei Zhang^{1

4}, Zongjiang Yu⁵, Xiangwei Meng^{1

6}

¹ Zibo Central Hospital, Zibo, China.
² Department of Oncology, Zibo Central Hospital, Zibo, China.
³ Department of Cardiology, Zibo Central Hospital, Zibo, China.
⁴ Department of Orthopedics, Zibo Central Hospital, Zibo, China.
⁵ CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, China.
⁶ Department of Drug Clinical Trials, Zibo Central Hospital, Zibo, China.

No abstract available

Keywords: STING agonists; cancer immunotherapy; immune suppression; macrophage polarization; tumor microenvironment (TME).

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.